UK AbbVie case augurs single EU medicines market
This article was originally published in Scrip
Executive Summary
A victory in the UK Court of Appeal for parallel trader Chemistree against AbbVie could be a step towards a European single market for pharmaceuticals and help reduce drug shortages, said the law firm that represents Chemistree, Matthew Arnold & Baldwin. The case could have important ramifications for EU competition law and how pharma firms manage their supply chains.